Eloxx Pharmaceuticals (OTCMKTS:ELOXD – Get Free Report) is expected to be releasing its resultson Tuesday, November 10th. Analysts expect Eloxx Pharmaceuticals to post earnings of ($0.5767) per share for the quarter.
Eloxx Pharmaceuticals Price Performance
OTCMKTS ELOXD remained flat at $6.20 on Tuesday. The firm has a 50 day moving average of $6.20 and a 200 day moving average of $3.76. Eloxx Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $10.00.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s approach centered on ribosome modulation, a strategy intended to encourage cellular machinery to read through certain premature stop signals in genetic sequences.
Its lead investigational product, ELX-02, was a synthetic aminoglycoside designed to promote nonsense-mutation read-through.
See Also
- Five stocks we like better than Eloxx Pharmaceuticals
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
